Biostem Technologies Inc (BSEM)

$6.74 +0.50 (8.01%)
Market Cap 104.94M
Revenue (ttm) 0.00
Net Income (ttm) 0.00
EPS (ttm) N/A
PE Ratio 7.91
Forward PE 23.17
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 90,000
Avg Vol 119,018
Day's Range N/A - N/A
Shares Out 16.82M
Stochastic %K 50%
Beta -0.38
Analysts Strong Buy
Price Target $25.50

Company Profile

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of...

Industry: Biotechnology
Sector: Healthcare
Phone: 954 380 8342
Address:
4901 Northwest 17th Way, Suite 606, Fort Lauderdale, United States
GmanPA
GmanPA Apr. 7 at 11:03 PM
$BSEM Per Barchart: Support & Resistance 3rd Resistance Point 7.4765 2nd Resistance Point 6.7833 1st Resistance Point 6.2366 Last Price 5.6900 1st Support Level 4.9967 2nd Support Level 4.3035 3rd Support Level 3.7568
0 · Reply
IRISHMIKE1
IRISHMIKE1 Apr. 7 at 8:41 PM
$BSEM Alright ! Back up over $5 ! We should continue on up over $6. With the forward guidance given with earnings we know we are headed up. The uplifting should be announced fairly soon!
0 · Reply
prismmarketview
prismmarketview Apr. 2 at 4:32 PM
PRISM Mid-Day Movers: Pharmaceuticals and Global Health are Today’s Leaders. Biodexa Pharmaceuticals (Nasdaq: $BDRX) is surging to about $1.05, up roughly 70% on heavy volume, yet still down over 90% in the past year as it heads into an April 6, 2026 1‑for‑5 ADR reverse split and remains a speculative, catalyst‑driven oncology play in tough‑to‑treat cancers. Lexaria Bioscience (Nasdaq: $LEXX) is trading just under $1.00, up about 17% as investors eye upcoming GLP‑1 catalysts following positive Human Pilot Study #5 data showing its oral DehydraTECH‑liraglutide performed comparably to injected Saxenda and kicking off a 2026 R&D program with new human and multi‑arm animal GLP‑1 studies. Other Notable Movers: BioStem Technologies ( $BSEM) up 16% Korro Bio ( $KRRO) up 10% Lipocine Inc ( $LPCN) down -78% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-global-health-are-todays-leaders/
0 · Reply
idkmikes57
idkmikes57 Apr. 1 at 3:51 PM
$BSEM
0 · Reply
GlobalInsights
GlobalInsights Mar. 31 at 2:18 PM
$BSEM Good to see the audit complete. What they show is the original 2024 results were announced, and many investors bought based on those results, have now been reinstated from $301.8m to $69.7m because of incorrect accounting practices. Similar declines occured in 2025 in the 1st half before redefining their accounting procedures. Those results were based on end user selling prices most likely at $2K per sq cm which is now being reduced to $127 in 2026. Those fooled by the inflated and incorrect accounting practices most likely have a legal justification for recover of their losses, but that’s up to you and your lawyer.
0 · Reply
Biotech_rabbi
Biotech_rabbi Mar. 30 at 1:54 PM
$BSEM Audit completed https://www.globenewswire.com/news-release/2026/03/30/3264494/0/en/BioStem-Technologies-Announces-the-Publication-of-its-Audited-Financial-Statements-for-Fiscal-Years-2024-and-2025.html
0 · Reply
GlobalInsights
GlobalInsights Mar. 25 at 1:52 AM
$BSEM Well I tried to tell people that this companies financial performance was way overstated and that the company leadership kept hyping and misrepresenting the reality of their business model. It’s interesting that they continue to hype the 97% GM in Q4 which can only have occured if they were selling products at $2K+ per sq cm, which will now drop to $127 per sq cm. All their hype & misrepresenting the reality of their business model really opens them up to shareholder lawsuits. A lot of people were fooled into investing and driving the shares all the way up to $28 at one point. I feel bad for all those that invested in this and lost money. Guess those investors have learned a valuable lesson. If it seems too good to be true it probably isn’t.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 24 at 9:19 PM
$BSEM Q4 '25 Earnings Results & Recap BioStem anticipates Q1 2026 revenue to be $5M to $6M, with the physician office business down significantly. BioStem expects sequential and year-over-year growth in the hospital business in the second half of 2026.
0 · Reply
jcooptechit
jcooptechit Mar. 24 at 6:59 PM
$BSEM READY TO RIP AGAIN? SAME $5 BASE… LAST TIME IT RAN TO $8+ BioStem is setting up in a very familiar zone and history says this could get explosive. 📊 THEN vs NOW: 🔸 Previously based around $5 and ran to $8+ 🔸 Now back in the $5.00–$5.25 support zone 📊 KEY LEVELS TO WATCH: ▫️ Support: $5.00 – $5.25 ▫️ Pivot: $6.12 ▫️ Breakout trigger: $7.16 ▫️ Targets: $8.29 - $9.12 - $9.95+ This is NOT your typical OTC name: 🔸 7 straight profitable quarters 🔸 Strong fundamentals 🔸 Nasdaq uplisting catalyst in play 🔸 $25.50 price target floating out there Tight base + proven explosive history + major catalysts = potential momentum move at ANY moment. ⚡ Last time this sat here… it didn’t stay quiet for long. If BSEM reclaims $6–$7 with volume, this could move FAST. Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
Rampart1
Rampart1 Mar. 24 at 6:46 PM
(OTC: $BSEM) BioStem Technologies🧬 🔥WATCHING THIS ALL OF 2026 DUE TO THE $25 PRICE TARGET & UPLISTING POSSIBILITY!👀 ✅Seven Profitable Quarters and a $25.50 Zacks Target ✅NASDAQ Uplisting in focus 2026 BioStem Technologies ($BSEM) Headed into 2026 With Transformational $40M Acquisition, Expanding into Acute & Hospital-Based Wound Care, Seven Straight Profitable Quarters. 🚨 Breaking: $BSEM (BioStem Technologies) kicks off 2026 with a transformational acquisition of BioTissue Holdings' surgical & wound care business, valued at up to $40M, adding established products Neox® and Clarix® and expanding into hospitals, ASCs, burns, trauma & soft-tissue repair. With 7 consecutive profitable quarters, 88.5% gross margins, $10.5M in quarterly revenue, and $29M in incremental annual revenue expected from the acquisition, BSEM stands out as a rare profitable small-cap in regenerative medicine. Communicated Disclaimer https://tinyurl.com/DoctorDDDisclaimer
0 · Reply
Latest News on BSEM
No data available.
GmanPA
GmanPA Apr. 7 at 11:03 PM
$BSEM Per Barchart: Support & Resistance 3rd Resistance Point 7.4765 2nd Resistance Point 6.7833 1st Resistance Point 6.2366 Last Price 5.6900 1st Support Level 4.9967 2nd Support Level 4.3035 3rd Support Level 3.7568
0 · Reply
IRISHMIKE1
IRISHMIKE1 Apr. 7 at 8:41 PM
$BSEM Alright ! Back up over $5 ! We should continue on up over $6. With the forward guidance given with earnings we know we are headed up. The uplifting should be announced fairly soon!
0 · Reply
prismmarketview
prismmarketview Apr. 2 at 4:32 PM
PRISM Mid-Day Movers: Pharmaceuticals and Global Health are Today’s Leaders. Biodexa Pharmaceuticals (Nasdaq: $BDRX) is surging to about $1.05, up roughly 70% on heavy volume, yet still down over 90% in the past year as it heads into an April 6, 2026 1‑for‑5 ADR reverse split and remains a speculative, catalyst‑driven oncology play in tough‑to‑treat cancers. Lexaria Bioscience (Nasdaq: $LEXX) is trading just under $1.00, up about 17% as investors eye upcoming GLP‑1 catalysts following positive Human Pilot Study #5 data showing its oral DehydraTECH‑liraglutide performed comparably to injected Saxenda and kicking off a 2026 R&D program with new human and multi‑arm animal GLP‑1 studies. Other Notable Movers: BioStem Technologies ( $BSEM) up 16% Korro Bio ( $KRRO) up 10% Lipocine Inc ( $LPCN) down -78% https://prismmarketview.com/prism-mid-day-movers-pharmaceuticals-and-global-health-are-todays-leaders/
0 · Reply
idkmikes57
idkmikes57 Apr. 1 at 3:51 PM
$BSEM
0 · Reply
GlobalInsights
GlobalInsights Mar. 31 at 2:18 PM
$BSEM Good to see the audit complete. What they show is the original 2024 results were announced, and many investors bought based on those results, have now been reinstated from $301.8m to $69.7m because of incorrect accounting practices. Similar declines occured in 2025 in the 1st half before redefining their accounting procedures. Those results were based on end user selling prices most likely at $2K per sq cm which is now being reduced to $127 in 2026. Those fooled by the inflated and incorrect accounting practices most likely have a legal justification for recover of their losses, but that’s up to you and your lawyer.
0 · Reply
Biotech_rabbi
Biotech_rabbi Mar. 30 at 1:54 PM
$BSEM Audit completed https://www.globenewswire.com/news-release/2026/03/30/3264494/0/en/BioStem-Technologies-Announces-the-Publication-of-its-Audited-Financial-Statements-for-Fiscal-Years-2024-and-2025.html
0 · Reply
GlobalInsights
GlobalInsights Mar. 25 at 1:52 AM
$BSEM Well I tried to tell people that this companies financial performance was way overstated and that the company leadership kept hyping and misrepresenting the reality of their business model. It’s interesting that they continue to hype the 97% GM in Q4 which can only have occured if they were selling products at $2K+ per sq cm, which will now drop to $127 per sq cm. All their hype & misrepresenting the reality of their business model really opens them up to shareholder lawsuits. A lot of people were fooled into investing and driving the shares all the way up to $28 at one point. I feel bad for all those that invested in this and lost money. Guess those investors have learned a valuable lesson. If it seems too good to be true it probably isn’t.
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 24 at 9:19 PM
$BSEM Q4 '25 Earnings Results & Recap BioStem anticipates Q1 2026 revenue to be $5M to $6M, with the physician office business down significantly. BioStem expects sequential and year-over-year growth in the hospital business in the second half of 2026.
0 · Reply
jcooptechit
jcooptechit Mar. 24 at 6:59 PM
$BSEM READY TO RIP AGAIN? SAME $5 BASE… LAST TIME IT RAN TO $8+ BioStem is setting up in a very familiar zone and history says this could get explosive. 📊 THEN vs NOW: 🔸 Previously based around $5 and ran to $8+ 🔸 Now back in the $5.00–$5.25 support zone 📊 KEY LEVELS TO WATCH: ▫️ Support: $5.00 – $5.25 ▫️ Pivot: $6.12 ▫️ Breakout trigger: $7.16 ▫️ Targets: $8.29 - $9.12 - $9.95+ This is NOT your typical OTC name: 🔸 7 straight profitable quarters 🔸 Strong fundamentals 🔸 Nasdaq uplisting catalyst in play 🔸 $25.50 price target floating out there Tight base + proven explosive history + major catalysts = potential momentum move at ANY moment. ⚡ Last time this sat here… it didn’t stay quiet for long. If BSEM reclaims $6–$7 with volume, this could move FAST. Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
Rampart1
Rampart1 Mar. 24 at 6:46 PM
(OTC: $BSEM) BioStem Technologies🧬 🔥WATCHING THIS ALL OF 2026 DUE TO THE $25 PRICE TARGET & UPLISTING POSSIBILITY!👀 ✅Seven Profitable Quarters and a $25.50 Zacks Target ✅NASDAQ Uplisting in focus 2026 BioStem Technologies ($BSEM) Headed into 2026 With Transformational $40M Acquisition, Expanding into Acute & Hospital-Based Wound Care, Seven Straight Profitable Quarters. 🚨 Breaking: $BSEM (BioStem Technologies) kicks off 2026 with a transformational acquisition of BioTissue Holdings' surgical & wound care business, valued at up to $40M, adding established products Neox® and Clarix® and expanding into hospitals, ASCs, burns, trauma & soft-tissue repair. With 7 consecutive profitable quarters, 88.5% gross margins, $10.5M in quarterly revenue, and $29M in incremental annual revenue expected from the acquisition, BSEM stands out as a rare profitable small-cap in regenerative medicine. Communicated Disclaimer https://tinyurl.com/DoctorDDDisclaimer
0 · Reply
jcooptechit
jcooptechit Mar. 24 at 3:07 PM
$BSEM FDA SHIFT + CLINICAL OUTPERFORMANCE = BIG OPPORTUNITY 🔬 BioStem is already aligned with where the FDA is heading and the market hasn’t priced it in yet. Strong Clinical Data 🔹 Published DFU trial showed superior outcomes vs standard care 🔹 2x higher likelihood of lasting wound closure FDA Tailwind 🔹 FDA now backing Bayesian trial methods 🔹 BSEM already using them → potential for faster validation + approvals Tech That Matters 🔹 BioRetain + CryoTek preserve tissue = better healing results 🔹 Expanding into VLU + DFU studies using same approach 💥 BOTTOM LINE: BSEM is combining better outcomes + FDA-aligned methodology which creates a powerful setup for growth and potential re-rating. With uplisting potential and a $25.50 PT narrative building… this is one to watch closely. Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
griffinrc23
griffinrc23 Mar. 24 at 2:21 PM
BioStem Technologies, Inc. (OTCQB: $BSEM) started 2026 with a major strategic milestone, completing the acquisition of BioTissue Holdings’ surgical and wound care business in a deal valued at up to $40 million. The upfront payment of $15 million, with additional milestones tied to FDA clearances and commercial targets, brings established products like Neox® and Clarix® under BSEM’s umbrella. These additions immediately expand the company’s commercial reach into hospital inpatient, outpatient, and ambulatory surgery center settings, while creating a direct pathway into high-value segments such as surgical wounds, burns, trauma, and soft-tissue repair. In its most recent quarter, the company reported $10.5 million in revenue, $0.8 million in GAAP net income, $2.7 million in adjusted EBITDA, and gross margins of 88.5%. Communicated disclaimer: https://lnkd.in/ePE5Jjq5
0 · Reply
jcooptechit
jcooptechit Mar. 24 at 1:57 PM
$BSEM Keep a close eye on BioStem! Major potential success story in the making. $ACXP $ANTX $CTMX $TRAW
0 · Reply
JTE_Theta
JTE_Theta Mar. 24 at 1:50 PM
$BSEM: From OTC to Nasdaq? The $25 Target Story Heating Up BioStem Technologies Inc. is a small cap MedTech company focused on advanced wound care using placental derived tissue. Following a recent acquisition, it’s expanding into surgical and hospital markets, positioning as a full spectrum player. Bullish Highlights🔻 • Nasdaq Uplisting 2026: Could unlock institutional capital + drive re rating • $25.50 Price Target 🎯 Zacks Small Cap Research sees major upside based on growth, profitability, and expanding market reach • 7 Profitable Quarters: Rare for a micro cap • $40M Acquisition: Expands into higher value care settings • Clinical Edge: BioREtain backed by RCT data 🧬 Bottom Line: If BioStem executes on its uplisting and integrates its acquisition successfully, this could shift from an overlooked OTC name to a re rated institutional growth story. CommunicationDisclaimer:http://tinyurl.com/muaeeetn
0 · Reply
jcooptechit
jcooptechit Mar. 24 at 1:43 PM
$BSEM NASDAQ UPLIST + $25.50 TARGET = A RE-RATING STORY IN THE MAKING 🏦 Nasdaq uplisting in progress ➖ Audits + SEC process underway ➖ Unlocks institutional access, liquidity, and visibility ➖ Historically where small caps see valuation expansion 🎯 Zacks Price Target: $25.50 ▫️ Signals a massive disconnect vs current levels ▫️ Based on profitability, clinical validation, and growth trajectory 📈 Fundamentals already there: ➖ 7 consecutive profitable quarters (rare in MedTech) ➖ 88.5% gross margins ➖ $16M cash, scaling without heavy dilution 🧬 $40M acquisition = growth accelerator ▫️ Expands into acute + hospital-based wound care ▫️ Adds new revenue streams + market access ⚡ THE SETUP: Profitable + expanding + uplisting catalyst pending. If BSEM secures Nasdaq, this could shift from an overlooked OTC name to an institutional MedTech play overnight. Watch closely. Communicated - Disclaimer: https://fh.bio/jcoop
0 · Reply
ZTRADEZ_LLC
ZTRADEZ_LLC Mar. 24 at 1:39 PM
(OTC: $BSEM) BioStem Technologies🧬 🔥WATCHING THIS ALL OF 2026 DUE TO THE $25 PRICE TARGET & UPLISTING POSSIBILITY!👀 ✅Seven Profitable Quarters and a $25.50 Zacks Target ✅NASDAQ Uplisting in focus 2026 BioStem Technologies ($BSEM) Headed into 2026 With Transformational $40M Acquisition, Expanding into Acute & Hospital-Based Wound Care, Seven Straight Profitable Quarters. 🚨 Breaking: (BioStem Technologies) kicks off 2026 with a transformational acquisition of BioTissue Holdings' surgical & wound care business, valued at up to $40M, adding established products Neox® and Clarix® and expanding into hospitals, ASCs, burns, trauma & soft-tissue repair. With 7 consecutive profitable quarters, 88.5% gross margins, $10.5M in quarterly revenue, and $29M in incremental annual revenue expected from the acquisition, BSEM stands out as a rare profitable small-cap in regenerative medicine. Communicated Disclaimer https://www.ztradez.net/communicated-disclaimer $ONDS $UGRO
0 · Reply
LewisDaKat
LewisDaKat Mar. 23 at 10:30 PM
$BSEM BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair https://marketwirenews.com/stock/bsem/news/biostem-appoints-jodi-ungrodt-to-board-of-directors--5623010907692425.html?utm_source=stocktwits
0 · Reply
IRISHMIKE1
IRISHMIKE1 Feb. 18 at 6:08 PM
$BSEM Headed back up! Let’s go $7 by Friday!!!
0 · Reply
NewsAndFilings
NewsAndFilings Feb. 6 at 10:54 PM
Biotech & Healthcare: $CSDX, $NWBO, $BSEM, $RDGL, $NRXBF Emerging Stocks to Watch https://thestreetreports.com/biotech-healthcare-csdx-nwbo-bsem-rdgl-nrxbf-emerging-stocks-to-watch/
1 · Reply
IRISHMIKE1
IRISHMIKE1 Feb. 5 at 9:15 PM
$BSEM markets all red and this keeps plugging away and going back up!
1 · Reply
DiamondCapital
DiamondCapital Feb. 5 at 2:16 PM
News article out now!! Covering $CSDX, $NWBO, $BSEM, $RDGL, $NRXBF https://thestreetreports.com/biotech-healthcare-csdx-nwbo-bsem-rdgl-nrxbf-emerging-stocks-to-watch/ Biotech & Healthcare: CSDX, NWBO, BSEM, RDGL, NRXBF Emerging Stocks to Watch
2 · Reply
Thegoatime
Thegoatime Feb. 3 at 9:01 PM
$BSEM I recently bought some shares. What should I know about the stock?
0 · Reply